Across TCGA pan-cancer cohorts, SNORD113-9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD113-9 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SNORD113-9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD113-9 expression acts as an unfavorable survival marker.
SKCM are the cancer types where SNORD113-9 Mutation most reproducibly stratifies survival.